Merckand Parexel International have entered into a strategic alliance thatwill see the CRO provide global clinical development services fordesignated biosimilar candidates to Merck BioVentures, a division ofMerck.
The agreement also establishes a dedicated Merck BioVentures unit within the Parexel organisation.
MichaelKamarck, president of Merck BioVentures, says: “This agreementpositions Merck BioVentures for success with an industry leadingpartner that has the expertise and resources to conduct clinicaldevelopment of our diverse portfolio of candidates to allow timelydelivery of products to the marketplace.”
No further details of the agreement have been announced.
InDecember 2008, Merck established the bioventures division in December2008 to capitalise on its biologics manufacturing capabilities toproduce follow-on biologics.